BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
Acute lymphoblastic leukemia clinical trials and catalysts
Active industry-sponsored trials on ClinicalTrials.gov for acute lymphoblastic leukemia: 109 (68 sponsors; 10 newly posted in the last 180 days, 6 stopped in the last 180 days; 5 new-entrant sponsors). Momentum score 5.5, rank 87 of 91 on the disease-area ranking. As of 2026-11-18.
Phase distribution: Early Phase 1 3, Phase 1 33, Phase 2 46, Phase 3 10, Phase 4 0, N/A 17.
Most active sponsors, by phase
| Sponsor | Active trials | By phase | New (window) | Upcoming readouts |
|---|---|---|---|---|
| Amgen AMGN | 5 | P3 2, P2 3 | 0 | 0 |
| Novartis Pharmaceuticals NVS | 7 | P2 3, NA 2, P1 1, P3 1 | 0 | 2 |
| Orca Biosystems, Inc. | 3 | P3 1, P1 2 | 0 | 0 |
| AbbVie ABBV | 2 | P3 1, P2 1 | 0 | 0 |
| Ascentage Pharma Group Inc. AAPG | 2 | P3 1, P1 1 | 0 | 0 |
| Merck Sharp & Dohme LLC MRK | 2 | P2 1, P3 1 | 0 | 0 |
| Acacia Pharma Ltd | 1 | P3 1 | 0 | 0 |
| CSL Behring new entrant | 1 | P3 1 | 1 | 0 |
| Takeda TAK | 1 | P3 1 | 0 | 0 |
| Chongqing Precision Biotech Co., Ltd | 5 | P2 1, NA 1, P1 3 | 1 | 1 |
| Hebei Senlang Biotechnology Inc., Ltd. | 5 | P1 1, P2 2, NA 2 | 0 | 1 |
| PersonGen BioTherapeutics (Suzhou) Co., Ltd. | 4 | P1 2, P2 1, EARLY_P1 1 | 1 | 1 |
| AstraZeneca AZN | 3 | P2 3 | 0 | 0 |
| Juventas Cell Therapy Ltd. | 3 | P2 2, NA 1 | 0 | 0 |
| Miltenyi Biomedicine GmbH | 3 | NA 2, P1 1 | 1 | 0 |
| Ossium Health, Inc. | 3 | NA 2, P2 1 | 1 | 0 |
| Allotera Therapeutics | 2 | P2 1, NA 1 | 0 | 1 |
| Autolus Limited AUTL | 2 | P2 1, P1 1 | 0 | 0 |
| Bellicum Pharmaceuticals | 2 | P2 2 | 0 | 0 |
| Kite, A Gilead Company | 2 | P1 1, P2 1 | 0 | 0 |
| Pfizer PFE | 2 | NA 1, P2 1 | 0 | 0 |
| Sichuan Baili Pharmaceutical Co., Ltd. | 2 | P1 2 | 0 | 0 |
| Syndax Pharmaceuticals SNDX | 2 | P1 1, P2 1 | 1 | 0 |
| Allterum Therapeutics, Inc | 1 | P1 1 | 0 | 0 |
| AvenCell Therapeutics, Inc. | 1 | NA 1 | 0 | 0 |
New-entrant sponsors: CSL Behring.
Recently stopped trials
- NCT05291390 Armaceutica, Inc. - suspended: Change of protocol Pyronaridine in Acute Myeloid Leukemia (AML)
- NCT04601584 AO GENERIUM - terminated: The sponsor discontinued the development of the drug for reasons other than safety. GNR-084 Safety and Pharmacological Characteristics in Refractory or Relapse B-cell Precursor ALL
- NCT07556757 ImmunityBio, Inc. - terminated: Study was terminated prematurely by the Sponsor for reasons not related to the safety of study drug A Safety and Efficacy Study of CD-19 t-haNK in Patients With B-cell Acute Lymphoblastic Leukemia
- NCT05086315 Sanofi - terminated: Early discontinuation based on strategic sponsor decision not driven by any safety concerns. First-in-human Study of SAR443579 Infusion in Male and Female Children and Adult Participants With Relapsed or Refractor
- NCT05255601 Bristol-Myers Squibb - terminated: A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pedi
- NCT07196111 Guangzhou Bio-gene Technology Co., Ltd - withdrawn: Due to corporate strategic adjustment. BAFFR CAR-T Treatment for Relapsed/Refractory B-cell Tumors
Upcoming trial readouts (next 90 days)
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-12-30 est. | P2 | Allotera Therapeutics | NCT06514794 A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex) | T-cell Acute Lymphoblastic Leukemia; Lymphoblastic Lymphoma | recruiting | 125 |
| 2026-12-31 est. | P1/P2 | Chongqing Precision Biotech Co., Ltd | NCT04781634 a Clinical Research of CD19 and CD22 Targeted Prime CAR-T Cell in Relapsed/Refractory B-ALL | B-ALL | recruiting | 40 |
| 2026-12-31 est. | P1/P2 | Excyte Biopharma Ltd | NCT06580301 Study of YK012 in B-cell Acute Lymphoblastic Leukemia | B-cell Acute Lymphoblastic Leukemia | recruiting | 46 |
Readouts in the last 180 days
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-09-16 | P1/P2 | Cellectis S.A. CLLS | NCT04150497 Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01) | B-cell Acute Lymphoblastic Leukemia | active not recruiting | 45 |
| 2026-07-14 | P1/P2 | Ossium Health, Inc. | NCT05589896 A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malign | Acute Leukemia; Acute Lymphoblastic Leukemia; Acute Myeloid Leukemia; Acute Biphenotypic Leukemia; A | active not recruiting | 12 |
Landscape counts: ClinicalTrials.gov, industry lead sponsors, active statuses, via the free hosted BioCatalystFeed MCP tool condition_landscape (query "acute lymphoblastic leukemia"); readouts matched by condition text. Registry counts only; not a forecast.
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.